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OPEN
REVIEW
A1 beta-casein milk protein and other environmental
pre-disposing factors for type 1 diabetes
JSJ Chia1,8, JL McRae1,8, S Kukuljan2, K Woodford3, RB Elliott4, B Swinburn5 and KM Dwyer1,6,7
Globally type 1 diabetes incidence is increasing. It is widely accepted that the pathophysiology of type 1 diabetes is inﬂuenced by
environmental factors in people with speciﬁc human leukocyte antigen haplotypes. We propose that a complex interplay between
dietary triggers, permissive gut factors and potentially other inﬂuencing factors underpins disease progression. We present
evidence that A1 β-casein cows’ milk protein is a primary causal trigger of type 1 diabetes in individuals with genetic risk factors.
Permissive gut factors (for example, aberrant mucosal immunity), intervene by impacting the gut’s environment and the mucosal
barrier. Various inﬂuencing factors (for example, breastfeeding duration, exposure to other dietary triggers and vitamin D) modify
the impact of triggers and permissive gut factors on disease. The power of the dominant trigger and permissive gut factors on
disease is inﬂuenced by timing, magnitude and/or duration of exposure. Within this framework, removal of a dominant dietary
trigger may profoundly affect type 1 diabetes incidence. We present epidemiological, animal-based, in vitro and theoretical
evidence for A1 β-casein and its β-casomorphin-7 derivative as dominant causal triggers of type 1 diabetes. The effects of ordinary
milk containing A1 and A2 β-casein and milk containing only the A2 β-casein warrant comparison in prospective trials.
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INTRODUCTION
Type 1 diabetes, one of the most common chronic diseases
among children,1 is characterised by the selective loss of insulin-
producing pancreatic β-cells in genetically susceptible individuals,
but a trigger from the environment is generally needed.2 The
appearance at an early age of autoantibodies directed primarily
against one or both of insulin or glutamic acid decarboxylase, but
rarely against islet antigen-2, most likely establishes the onset of
this disease.2 Thereafter, other autoantibodies against either islet
antigen-2 or zinc transporter-8 might appear and the more that
appear, the greater the risk of rapid progression to clinical disease.
However, β-cell autoantibodies may be more representative of
reproducible biomarkers of type 1 diabetes pathogenesis and may
not be pathogenic themselves.2
There are marked variations worldwide in the incidence and
prevalence of type 1 diabetes.3 Incidence also varies considerably
between countries of close geographical proximity that have
populations with apparently similar racial/ethnic backgrounds.3,4
The incidence of type 1 diabetes in Iceland is less than half that in
Norway, but this difference cannot be explained by known genetic
factors because the distributions and frequencies of the known
human leukocyte antigen (HLA) class II genes, which affect
incidence, are similar in both countries.5 Evidence of the
involvement of differential exposure to environmental factors
comes from studies in monozygotic twins, which suggest that only
13–33% are pair-wise concordant.6,7
An increasing incidence in type 1 diabetes has been observed in
most countries. Data from 20 registers in 17 European countries
showed a mean increase in children aged o15 years of 3.9% per
annum between 1989 and 2003.8 The annual rates of increase
were generally higher in Eastern European countries (Poland 9.3%,
Romania 8.7%, Czech Republic 6.7%) than in western European
countries (Spain [Catalonia] 0.6%, Finland 2.4%, Germany [Dussel-
dorf] 4.7%). However, preliminary evidence from Sweden shows
that since 2000, the incidence rate has peaked and started to
decline among children aged o15 years.9 Recent evidence points
to a remarkable increase in China. In Shanghai, the incidence
among children aged ⩽ 15 years increased at a rate of 14.2% per
year between 1997 and 2011, from a low baseline of 1.5 per
100 000 in 1997–2001 to 5.5 per 100 000 in 2007–2011.10 In
Zhejiang, a major city south of Shanghai at an earlier stage of
economic development, the mean incidence in adolescents aged
⩽ 19 years increased at a rate of 12.0% per year, from 1.22 per
100 000 in 2007 (age standardised) to 2.48 per 100 000 in 2013.11
The greatest increase in Zhejiang was in children aged o5 years
with a rate of 33.61% per year. It is notable that the increasing
incidence of type 1 diabetes in China in recent years is mirrored by
an increase in per capita dairy product consumption among urban
residents of 12 kg from nearly 6 kg in 1992 to 18 kg by 2006.12
These ﬁndings suggest that environmental factors are signiﬁcant
forces in type 1 diabetes incidence increases.
It is widely acknowledged that genetic and environmental
factors interact to precipitate the progression to type 1
diabetes.2,13 Genetic susceptibility factors are well known in terms
of the HLA-DR3-DQ2 and HLA-DR4-DQ8 haplotypes, alone or in
combination, as reviewed by Pociot and Lernmark.2
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The contribution of environmental factors is highlighted by: (1)
the relatively small proportion of individuals with genetic
susceptibility manifesting disease;14 and (2) observations that
the incidence of type 1 diabetes has increased fastest in recent
generations in developed countries.15
Various environmental factors have been implicated and
include pre- and post-natal exposures,13 but we argue that cows’
milk A1 β-casein protein is a key environmental trigger that may
explain a signiﬁcant rise in type 1 diabetes and the different
prevalence rates. This does not exclude an effect of other dietary
triggers, including gluten/prolamines16 and bovine insulin in cows’
milk-based infant formula,17 which has been reported to inﬂuence
insulin autoantibody formation in infants fed a conventional cows’
milk-based formula before 3 months of age.17 Changes in modern
food processing and storage techniques may also impact:18 for
example, heat treatment of foods in the presence of sugars
(lactose, glucose, fructose) or ascorbic acid, which can produce
glycated products, have diabetogenic effects in mouse models.19
Furthermore, inhibition of advanced glycation product receptors
has been shown to inhibit autoimmune diabetes in mice.20
Permissive gut factors are coexisting mediating mechanisms,
which may be involved to varying degrees to favour or enhance
the pathogenesis of diabetes (Figure 1) and include factors such as
aberrant mucosal immunity, local inﬂammation and variations in
gut permeability.21,22 These may be singularly permissive or
interplay as a series of cascading permissive factors that are
causally related in sequence.23 There are also likely to be many
inﬂuencing factors involved in responses to dietary triggers,
permissive gut factors and progression towards type 1 diabetes,
such as short duration/no breastfeeding, caesarean delivery rates
and magnitude of exposure to vitamin D (Figure 1).13,16,24–26 It is
also reasonable to expect that some risk factors common to
speciﬁc populations in speciﬁc geographical locations may be
expressed at the population level, while others may only be
apparent within populations. Confounder variables, including
birth weight, gestational age, Apgar score and maternal age,
may also inﬂuence disease onset.
Given the pathophysiology of type 1 diabetes (that is, an
environmental trigger initiates an autoimmune cascade of events),
it is plausible that its incidence can be reduced by removing
exposure to individual environmental triggers. This is consistent
with the notion that many permissive gut factors and other
inﬂuencing factors contribute to diabetes outcomes in the
presence of a trigger, but are not themselves causal triggers.
Early exposure to cows’ milk and cereals and other inﬂuencing
factors for type 1 diabetes
β-cell autoimmunity emerges early in life and early feeding
practices may modulate the risk of type 1 diabetes. Indeed, case–
control and prospective cohort studies suggest that early child-
hood exposure to cows’ milk is an inﬂuencing environmental risk
factor in the development of type 1 diabetes.27–29 This could be a
surrogate marker for short or no breastfeeding, and an inverse
relationship between breastfeeding and the incidence of type 1
diabetes has been reported.30 However, whether the absence of
breastfeeding confers increased risk has not been conﬁrmed,
because some studies show no effect, others a predisposing effect
or a protective effect.14 One reason for these diverse results may
be that many studies do not distinguish between exclusive or
partial breastfeeding (but instead consider ‘overall’ breastfeeding).
Furthermore, the duration of exclusive breastfeeding together
with the age of introduction of cows’ milk proteins may inﬂuence
the outcomes. Additional confusion may be introduced by
between-country differences in weaning practices, such as
weaning to hydrolysed versus intact protein infant formula, or
introducing cereal food rather than infant formula as a ﬁrst infant
‘food’.31
If infant age at the introduction to cows’ milk protein is
considered together with breastfeeding duration, introducing
cows’ milk to infants before 2 months old, compared with
4 months or older is a strong inﬂuencing environmental factor for
type 1 diabetes (rather than breastfeeding duration per se).25 This
was demonstrated in a nationwide Finnish case–control study of
690 children with type 1 diabetes (o15 years old), in which
univariate analysis showed that type 1 diabetes risk was doubled
by the introduction of bovine dairy proteins before 2 months of
age.32 Furthermore, multivariate analyses of infant age at
introduction to dairy and breastfeeding duration showed that
early dairy introduction (before 2 months old) was the most
important risk factor and that the observed effects of breastfeed-
ing duration in the univariate analysis were explained by their
correlation with early bovine dairy introduction in the multivariate
analysis.
Early exposure to complex dietary proteins may increase type 1
diabetes-associated β-cell autoimmunity responses in genetically
at-risk children, and feeding extensively hydrolysed cows’ milk
protein formula (which does not contain intact proteins) may
confer better outcomes compared with feeding intact cows’ milk
protein formula.33 Positivity for two or more autoantibodies is
associated with a risk of progression to clinical diabetes of ~ 60%
over 10 years and ~ 80% over 15 years.34 The TRIGR type 1
diabetes primary prevention pilot study of 230 at-risk Finnish
children was established to determine whether weaning infants to
an extensively hydrolysed-casein milk protein formula versus an
80% intact cows’ milk protein and 20% hydrolysed casein milk
protein formula reduced the proportion of children positive for
two or more autoantibodies.25 Although the pilot study showed
that infants weaned to the extensively hydrolysed-protein formula
experienced a 50% decrease in the cumulative incidence of β-cell
autoimmunity,25 this was not sustained in the multinational
double-blind randomised clinical follow-up trial of 2159 geneti-
cally susceptible infants with an observation period of 7.0 years.33
The authors concluded that introduction to an extensively
hydrolysed casein versus partially hydrolysed casein cows’ milk
protein formula for at least 2 months was insufﬁcient to cause a
difference in diabetes-associated autoantibody responses in at-risk
infants breastfed for ⩾ 2 months. However, it is unknown whether
an amino acid-based formula or a longer intervention period also
has an effect.
Studies investigating an association between cows’ milk
consumption and type 1 diabetes have yielded conﬂicting results.
Figure 1. Proposed model for progression to type 1 diabetes in genetically susceptible people.
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Some studies have not found an association between early
exposure to cows’ milk and type 1 diabetes.31,35–37 This may be
explained in part by the interaction between early exposure to
cows’ milk-based infant formula and other environmental
inﬂuencing factors. For example, enteral virus infection is
commonly cited as being involved in type 1 diabetes, but it
may be the combination of enteral virus infection and early
exposure to cows’ milk that is important in determining
progression to type 1 diabetes-associated autoimmunity.38 Using
regression analysis, Lempainen et al.38 reported a combined effect
of enterovirus infection before 12 months of age and early
exposure to cows’ milk infant formula (before 3 months) on type 1
diabetes-associated autoantibodies in the Finnish Diabetes Pre-
diction and Prevention Study. Furthermore, differences in cows’
milk proteins, and consequently infant formula protein composi-
tion, could inﬂuence the ﬁndings associated with cows’ milk
protein consumption and type 1 diabetes risk.4 The magnitude/
amount of cows’ milk protein exposure represents another
inﬂuencing factor as demonstrated in a Finnish case–control
study, where children with type 1 diabetes (n= 33) had a greater
likelihood of high milk consumption (4540 ml milk per day) (odds
ratio 5.37, 95% conﬁdence interval 1.6–18.4) compared with
control children consuming o540 ml milk per day (n= 254).29
Introducing cereal foods before ~ 3 months of age is also
associated with early β-cell autoimmunity,31 and the cereal protein
gluten has diabetogenic effects in rodents.39 Although the
practical implications of cereals in infant feeding may be limited
because infant feeding guidelines in developed countries do not
recommend such early introduction to cereals, Norris et al.31
suggested that early (o4 months old) and late (⩾7 months old)
exposure to cereals was associated with increased risk of β-cell
autoimmunity.31 This idea of an opportune ‘window’ for certain
food introduction has received attention in terms of the best time
to introduce allergens to minimise allergy development in at-risk
infants.40
Recent evidence from Lamb et al.41 indicates that cows’ milk
protein may inﬂuence the entire type 1 diabetes disease
process. In this prospective Diabetes Autoimmune Study in the
Young (DAISY) childhood cows’ milk protein was associated with
islet autoimmunity in children with low/moderate genetic risk of
type 1 diabetes, but not with high genetic risk. However, once islet
autoimmunity was established cows’ milk protein was associated
with an increased risk of progression to type 1 diabetes
independent of the underlying genetic risk. The timing of
introduction of cows’ milk protein was only signiﬁcant at a very
early age for the development of islet autoimmunity. The authors’
conclude that cows’ milk may be diabetogenic when consumed
throughout childhood, and may impact both early and later stages
of T1D development.
A1 β-casein milk protein: a primary dietary trigger for diabetes
Regional and between-country differences in the incidence of
type 1 diabetes are correlated with milk consumption.42 One of
the main milk proteins is β-casein, which accounts for about 30%
of the total protein in cows’ milk.43 Several variants of bovine
β-casein have been identiﬁed, which have differential cleavage
patterns in vivo stemming from their amino-acid sequences. Cows’
milk contains two major β-casein variants, known as the A1 and
A2 types.44 These variants differ by a single amino acid at position
67, with a histidine amino acid at this position in the A1 β-casein
type and proline in the A2 β-casein type. The histidine residue in
A1 β-casein allows cleavage of the preceding seven amino acids,
yielding the exogenous peptide β-casomorphin-7 (BCM-7)
(Figure 2).44 BCM-7 is a μ-opioid receptor agonist45 that can cross
the gastrointestinal wall and enter systemic circulation.46 μ-Opioid
receptors are expressed throughout the gastrointestinal tract and
elsewhere.47 As both the cereal protein gluten and cows’ milk
protein A1 β-casein have been implicated as dietary antigens in
type 1 diabetes, it is of note that gluten also releases the 7-amino-
acid opioid peptide gliadorphin-7.48 Gluten has also been
associated with increased T-cell reactivity in some patients with
newly diagnosed type 1 diabetes.49
The proline residue at position 67 in A2 β-casein minimises the
likelihood of cleavage. Notably, human breast milk β-casein
contains a proline in the homologous position as bovine A2
β-casein protein, so human β-casein is of the A2 type.50 Thus,
breastfeeding during early infancy eliminates early exposure to
A1 β-casein, although BCM-7 derived from dietary bovine A1
β-casein may be transferred to the infant via human breast milk.51
Bovine milk A1 β-casein content varies considerably by region,
depending on herd genetics. In addition, A1 β-casein consump-
tion correlates signiﬁcantly with type 1 diabetes incidence and
shows a stronger correlation than does milk consumption
per se.4,42 Laugesen and Elliott examined food consumption data
from 19 ‘health care afﬂuent’ developed countries to investigate
correlations between food consumption and the rates of type 1
diabetes.42 Strong correlations were identiﬁed between the
consumption of A1 β-casein, but not A2 β-casein, and the
incidence of type 1 diabetes. Incidence was highest in Finland and
Sweden (countries with the highest A1 β-casein consumption/per
capita) and lowest in Venezuela and Japan (countries with
the lowest A1 β-casein consumption/per capita) (Figure 3).42 The
correlation between A1 β-casein and type 1 diabetes was
extremely high, with an r value of 0.92, the strongest of 15
correlates. Although ecological analyses can be subject to either
ecological fallacies and/or confounding, no plausible explanation
Figure 2. Structures of A1 and A2 β-casein. Adapted from Pal et al.44
Figure 3. Correlation between A1 β-casein supply per capita in 1990
and type 1 diabetes incidence (1990–1994) in children aged 0–14
years in 19 countries. (r= 0.92; 95% conﬁdence interval: 0.72–0.97;
Po0.0001). Dotted lines are the 95% conﬁdence limits of the
regression line. Reproduced with permission from R Elliott and The
New Zealand Medical Journal (2003).42
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has emerged in relation to this speciﬁc dataset that would
invalidate the evidential relationship. With these data, credence is
imparted by the very high correlations observed, by the
combination of high between-country variation (a factor of 280)
with the high variation in the intake of A1 β-casein (more than
ﬁve-fold variation), and by the high stability of the results to the
removal of any individual country from the analyses. Correlations
with A2 β-casein (r= 0.47), latitude (r= 0.65) and oats (r= 0.7) were
also signiﬁcant, but only A1 β-casein was signiﬁcant in multiple
regression analyses given the collinearity of these other variables
with A1 β-casein. Although it is possible the correlation was
created by a third, as yet unidentiﬁed common factor, none have
been proposed that could explain the high r value of 0.92 for A1
β-casein. On the balance of probabilities, A1 β-casein may be a
causal factor.
The more recent longitudinal data sets from Shanghai10 and
Zhejiang,11 combined with the threefold increase since 2000 of
per capita milk consumption in urban China,12 also give credence
to a link with a component of milk. Accordingly, the ecological
epidemiological data, although not proving causation, provide
powerful evidence that A1 β-casein is a causal factor in the
pathogenesis of type 1 diabetes.
Although it has been suggested that vitamin D deﬁciency or the
magnitude of exposure to vitamin D are inﬂuencing factors that
may explain these regional differences in the incidence of type 1
diabetes,26 there is limited supporting empirical evidence across
populations.42 Indeed, Birgisdottir et al.4 reported similarly strong
correlations between lower A1 β-casein consumption and the
incidence of type 1 diabetes in Iceland versus four other
Scandinavian countries in 2-year-old children, despite all countries
sharing similar latitudes, which is relevant to population vitamin D
status.
Animal studies: A1 β-casein as a dietary trigger for autoimmune
diabetes
The diabetogenic effects of milk protein were demonstrated in an
early study in BioBreeding (BB) rats,52 an animal model of
spontaneous autoimmune diabetes. Here 50% of rats developed
autoimmune diabetes when fed a standard laboratory diet
(background rate), which decreased to 15% in rats fed a basic,
semi-synthetic diet.52 However, when the basic, semi-synthetic
diet was supplemented with milk, 52% of rats developed
autoimmune diabetes. This rate was 35% in rats fed the gluten-
supplemented basic diet.
Since this study, additional animal studies have examined the
involvement of A1 β-casein cows’ milk protein and opioid
receptors.53,54 In the ﬁrst of these, non-obese diabetic (NOD)
mice were fed a basal diet supplemented with either A1 or A2
β-casein.54 While no mice fed the A2 β-casein diet developed
autoimmune diabetes, 47% of those fed the A1 β-casein diet
developed autoimmune diabetes. Co-administration of the opioid
receptor antagonist naloxone attenuated the effects of the A1
β-casein diet, suggesting the diabetogenic effects of the A1
β-casein diet were at least partly mediated via opioid receptors.
The second study was a multicentre trial of BB rats and NOD
mice performed by researchers in New Zealand, the United
Kingdom and Canada. This study provided limited and incon-
clusive evidence of differential effects of A1 and A2 β-casein.53 The
correct interpretation of this study is confounded by implementa-
tion events, including infection within the New Zealand mouse
colony and feed contamination of both A1 and A2 diets with
BCM-7 from partially hydrolysed A1 β-casein. The former was
acknowledged within the publication but the evidence of feed
contamination with BCM-7 was published only later.55
Human studies
No studies have compared the effects of A1 versus A2 β-casein in
milk on the progression towards type 1 diabetes or emergence of
associated antibodies in humans. However, β-casein was reported
to stimulate T-cell immune responses56 and antibody immune
responses,57,58 both of which may contribute to the development
of type 1 diabetes. Monetini et al.59 have shown that T-cell lines
speciﬁc to bovine β-casein can be isolated from the peripheral
blood of patients with type 1 diabetes and that these cell lines
react with multiple and different sequences of β-casein, particu-
larly towards the C-terminal portion. The same researchers also
detected signiﬁcantly higher levels of antibodies to β-casein in
formula-fed infants (n= 12) under 4 months of age compared with
exclusively breastfed infants (n= 16) (Po0.001) and in prepuber-
tal children with type 1 diabetes (n= 37) compared with age-
matched controls (n= 31) (P= 0.03).57 These ﬁndings may
represent manifestations of type 1 diabetes and increased
sensitivity to antibody reactions. However, in one of the only
human studies to investigate the differences in antibody
responses to A1 and A2 β-casein, Padberg et al.60 reported that
the ratio of A1 to A2 β-casein antibodies was higher in those with
type 1 diabetes than in controls (Po0.001). Nevertheless, the
signiﬁcance of these results in genetically at-risk children is open
to debate.
Previously, two potential pathways have been suggested as
being involved in the link between type 1 diabetes and A1
β-casein: (i) the opioid activity of BCM-7;54 and (ii) the similar
structures of β-casein and an epitope of the glucose transporter 2
(GLUT-2) expressed on β-cells (that is, immunological cross-
reactivity or molecular mimicry).61
In the former pathway, opioids like BCM-7 may interfere with
metabolic processes, including the regulation of glucose levels
and insulin production and these effects are partly prevented by
opiate receptor inhibitors such as naloxone.54,62 Such effects may
hasten or worsen progression to diabetes. In the second pathway,
exposure to A1 β-casein may promote the development of
autoantibodies that ultimately contribute to the cascade of events
culminating in the development of type 1 diabetes. Autoantibo-
dies to GLUT-2 have been detected in most patients with recent-
onset type 1 diabetes63 and reactivity of β-casein T-cell lines to
human insulinoma extracts and GLUT-2 peptide has been
reported.59 However, the full implications of these ﬁndings are
open to speculation because β-cell autoantibodies may not
necessarily be pathogenic: rather, they may represent reproduci-
ble biomarkers of the pathogenesis.2
Permissive gut factors linking type 1 diabetes and A1 β-casein:
intestinal microbiota, gut permeability and mucosal immunity
The current hypothesis for the pathogenesis of type 1 diabetes
considers permissive factors interacting at the gut level, including
aberrant intestinal microbiota, increased intestinal mucosal barrier
permeability and aberrant intestinal immune responses.22 During
infancy, the presence of commensal intestinal microbiota is critical
for various physiologic processes including stimulation of various
arms of the innate and adaptive immune systems.22 Gut
microbiota modulate gut immune function via the innate immune
system, such as intestinal epithelial cells and dendritic cells and via
the adaptive immune system, particularly intestinal T cells.64 The
gut immune system may also be involved in type 1 diabetes
development via the immunological link between the gut and
pancreas.64 In fact, NOD mice experience a higher type 1 diabetes
incidence in a germ-free environment,65 highlighting the environ-
mental impact on gut microbiota outcomes. In humans, low gut
microbe diversity of distinct organism types (that is, number,
amount and distribution) has been linked to type 1 diabetes and
β-cell autoimmunity.66
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The intestinal surface barrier is an important component of the
innate immune system, separating immunogenic material in the
intestinal lumen from an immunoreactive submucosa; this may be
affected by interactions between aberrant intestinal microbiota
and changes in gut barrier permeability.22 Previous studies in BB
rats using lactulose and mannitol (markers of gut permeability)
have shown that the intestine is highly permeable before the
onset of type 1 diabetes.67 Intestinal myeloperoxidase activities
and goblet cell density are also higher in these diabetes-prone
rats compared with controls, highlighting a concomitant early
intestinal inﬂammatory response. This is notable because inﬂam-
matory mediators can compromise epithelial barrier function and
further affect gut permeability. Notably, elevated intestinal
myeloperoxidase activity is evident in rodents fed A1 compared
with A2 β-casein.68 Humans genetically predisposed to type 1
diabetes exhibit intestinal barrier abnormalities.22 Because intest-
inal samples from ‘at-risk’ individuals show gut permeability
abnormalities in sugar permeability tests,69 these permeability
abnormalities may be present before the onset of clinical disease.
Similar results have been observed in patients with type 1
diabetes.70
Gut permeability abnormalities create opportunities for greater
intestinal immune system exposure to dietary antigens such as
proteins and peptides, causing altered immune activation and
intestinal inﬂammation.71 Although intestinal inﬂammation is a
prerequisite for progression to β-cell autoimmunity and early life
impaired barrier function may be an underlying cause of altered
responses to gut lumen antigens,71 it is unknown whether
aberrant responses to antigens cause intestinal inﬂammation
and increased gut permeability or vice versa.
Individually, these factors will be insufﬁcient for promoting the
onset of type 1 diabetes, but we propose that one or a
combination of these permissive gut factors, together with the
A1 β-casein dietary trigger, is generally necessary to precipitate
type 1 diabetes in genetically at-risk individuals. The evidence
base for the diabetogenic effects of milk, especially A1 β-casein,
ﬁts the paradigm of a requisite joint exposure to A1 β-casein plus
one or more permissive gut factors (which may also be subject to
inﬂuencing factors), either concurrently or sequentially, for the
induction of type 1 diabetes.
CONCLUSIONS
The evidence for milk and, particularly A1 β-casein, as a primary
dietary trigger for type 1 diabetes is intriguing although causation
remains unproven. The ecological evidence across populations is
particularly strong. Exclusive breastfeeding is widely regarded as
being protective against type 1 diabetes in early infancy, but its
beneﬁts may be lost if the mother supplements breast milk with
cows’ milk formula, or if the duration of breastfeeding is too short.
It is also conceivable that some dietary triggers might cross into
breast milk. These factors might contribute to the inconsistencies
in the reported associations between breastfeeding and type 1
diabetes. Latitude acting as a proxy for vitamin D exposure has
been suggested as a potential causal factor, but hypotheses
linking vitamin D as a causative trigger in type 1 diabetes have
been unrewarding. Thus, we suggest that factors such as vitamin
D may act as inﬂuencing or modifying factors, but not causal
factors. Furthermore, the geographical variability and the chron-
ological changes in type 1 diabetes incidence suggest that
changes to inﬂuencing factors and permissive gut factors may
have altered (for example, gut microbiome proﬁles), contributing
to the increasing incidence of type 1 diabetes.
If A1 β-casein is indeed the dominant causal trigger, then the
apparent inconsistent and therefore puzzling results with previous
milk studies may be explained. For example, the widespread
geographical variation in A1 to A2 β-casein ratio of milk products
combined with variable β-casein content of infant formulas, a
consequence of different casein to whey ratios of the formula-
tions, may complicate the interpretation of the data.
There are particular challenges associated with prospective
studies investigating milk per se as causative of type 1 diabetes.
These challenges relate to the ubiquity of milk in the diets in
developed countries and the long-term nature of any trials.
Inﬂuencing factors include the potential protective effects of
breastfeeding and its duration, and whether or not all bovine milk
is excluded from the diet of the mother as well as the baby.
However, the potential role of A1 β-casein as a causative trigger
for type 1 diabetes could be resolved by prospective studies in
genetically at-risk individuals, using milk diets from birth that do
not contain A1 β-casein, but which contain β-casein of the A2 type
exclusively.
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